Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

BACKGROUND: The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival (OS) data are now mature. METHODS: Women with ROC relapsing >6 months after...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Wagner, U, Marth, C, Largillier, R, Kaern, J, Brown, C, Heywood, M, Bonaventura, T, Vergote, I, Piccirillo, M C, Fossati, R, Gebski, V, Lauraine, E P
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2012
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3419956/
https://ncbi.nlm.nih.gov/pubmed/22836511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.307
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi